1 / 11

Spinal Muscular Dystrophy Market

Spinal muscular atrophy is a genetic disease affecting the part of the nervous system that controls voluntary muscle movement.u00a0<br>

DelveInsight
Download Presentation

Spinal Muscular Dystrophy Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Spinal Muscular Atrophy (SMA) Spinal muscular atrophy is a genetic disease affecting the part of the nervous system that controls voluntary muscle movement.  01 02 There are 5 SMA types - Type 0, Type 1, Type 2, Type 3, Type 4. 03 04 The majority of SMA prevalent population belongs to SMA Type 2 and SMA Type 3. SMA involves the loss of nerve cells called motor neurons in the spinal cord and is classified as a motor neuron disease. • DelveInsight © 2019 | All rights reserved

  2. Cases of SMA The total prevalent population of Spinal Muscular Atrophy in 7 major markets was 19,343 in 2017 while the total diagnosedprevalent population of Spinal Muscular Atrophy in 7 major markets was 17,094 in2017. • DelveInsight © 2019 | All rights reserved

  3. Market Outlook The total prevalence of Spinal Muscular Atrophy in the US is expected to increase at a CAGR of 0.77% for the study period of 2017-2028. The diagnosed prevalent population of Spinal Muscular Atrophy in 7MM is expected to increase at a CAGR of 0.88% for the study period. The market size of Spinal Muscular Atrophy in seven major markets is expected to increase from 1,317 Million in 2017 at a CAGR of 10.42%. • DelveInsight © 2019 | All rights reserved

  4. Emerging Therapies (Companies) AMIFAMPRIDINE PHOSPHATE (Drugs) RISDIPLAM ZOLGENSMA RELDESEMTIV • DelveInsight © 2019 | All rights reserved

  5. Report SMA Report Insights SMA Report Key Strengths SMA Report Assessment • Patient Population • Therapeutic Approaches • Pipeline Analysis • Market Size and Trends • Market Opportunities • Impact of upcoming Therapies • 10 Year Forecast • ComprehensiveCoverage •  Epidemiology Segmentation •  Drugs Uptake •  Highly Analyzed Market •  Key Cross Competition • Current Treatment Practices • Unmet Needs • Detailed Pipeline Product Profiles • Market Attractiveness • Market Drivers and Barriers SMA Report Insights SMA Report Key Strengths SMA Report Assessment • DelveInsight © 2019 | All rights reserved

  6. Complete Information For complete information on Spinal Muscular Atrophy - Market Insights, Epidemiology and Market Forecast-2028 please click the link below CLICK HERE OR Write Us At  info@delveinsight.com • DelveInsight © 2019 | All rights reserved

  7. About DelveInsight Mission 2 1 3 About To provide “insights across the value chain” and helping the organization to take a prudent business decision through the use and analysis of actionable market intelligence. The mission also is to provide the most effective result and efficient service with utmost client care for maintaining a long-term relationship with them. Vision DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for improving their performances to stay ahead of the competitors. To be the most trusted market research & business consulting firm in the world; and to continue enable the Pharma & Bio-Tech companies to achieve their goals with the best strategic insight and competitive solution. The vision also is inclusive of becoming a one-stop solution provider for the entire gamut of drug development process. • DelveInsight © 2019 | All rights reserved

  8. Service Offerings by DelveInsight 2 8 3 1 6 4 5 7 Market Intelligence Opportunity Assessment Forecasting Socialytics Competitive Analysis Pipeline Consulting Report Store • DelveInsight © 2019 | All rights reserved

  9. Contact Us info@delveinsight.com +91-11-4568 9769 www.delveinsight.com blog/delveInsight/ twitter/delveInsight LinkedIn/delveInsight • DelveInsight © 2019 | All rights reserved

More Related